3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Lymphoid
1
Head & Neck
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
16
Carcinoma, Non-Small-Cell Lung
7
Pancreatic Neoplasms
6
Melanoma
6
Breast Neoplasms
6
Carcinoma, Renal Cell
5
Lung Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Head and Neck Neoplasms
3
Colorectal Neoplasms
3
Uterine Cervical Neoplasms
2
Stomach Neoplasms
2
Small Cell Lung Carcinoma
2
Sarcoma
2
Ovarian Neoplasms
2
Neoplasms
2
Liver Neoplasms
2
Esophageal Squamous Cell Carcinoma
2
Endometrial Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Hepatocellular
2
Anus Neoplasms
2
Adenocarcinoma of Lung
2
Adenocarcinoma Of Esophagus
2
Adenocarcinoma
2
Uveal Melanoma
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Interventions
pembrolizumab
3
talimogene laherparepvec
1
spartalizumab
1
nanocis
1
fludarabine
1
avelumab
1
atezolizumab
1
aldesleukin
1
Technetium-99
1
TTI-621
1
Radiation
1
Proton Pump Inhibitors
1
Nivolumab
1
Lasers
1
Ipilimumab
1
Interleukin-2
1
Infracyanine green
1
Indocyanine Green
1
Hydrocortisone
1
Cyclophosphamide
1
Bleomycin
1
Antineoplastic Protocols
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Squamous Cell
×
spartalizumab
×
Breast
×
Clear all
NCT03058289
2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2
Completed
111 enrolled
21 charts